2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Adverse Events, Biological Processes, Apoptosis, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

3546 Glofitamab in combination with orelabrutinib and Bortezomib in high-risk relapsed/refractory mantle cell lymphoma: Preliminary Results of a prospective, single-center, phase II study

Qing Shi I, Certified Doctor, Yaohui Huang Jr2, Jiayin He3, Shu Cheng, MD4, Pengpeng Xu, MD5, Weili Zhao6, Li Wang III, MD7
1 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital; Shanghai Jiao Tong University School of Medicine, shanghai, China
2 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital; Shanghai Jiao Tong University School of Medicine, shanghai, China
3 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital; Shanghai Jiao Tong University School of Medicine, shanghai, China
4 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital; Shanghai Jiao Tong University School of Medicine, shanghai, China
5 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital; Shanghai Jiao Tong University School of Medicine, shanghai, China
6 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital; Shanghai Jiao Tong University School of Medicine, shanghai, China
7 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital; Shanghai Jiao Tong University School of Medicine, shanghai, China

Background: High-risk relapsed/refractory (R/R) mantle cell lymphoma (MCL)—defined by blastoid/pleomorphic histology, high Ki-67 proliferation index (≥30%), TP53 aberration (TP53 mutation and/or del(17p)), complex karyotype, high MCL International Prognostic Index (MIPI) score, or early progression after first-line therapy—carries a poor prognosis. Single-agent Bruton tyrosine kinase inhibitors (BTKi) provide limited durable benefit. Glofitamab, a CD20×CD3 T-cell engaging bispecific antibody, has shown high complete response (CR) rates as monotherapy in R/R MCL, including BTKi-exposed patients. Combining glofitamab with the BTKi orelabrutinib and the proteasome inhibitor bortezomib may deepen and broaden responses through complementary anti-tumor mechanisms. We report preliminary efficacy and safety data of this triplet regimen in high-risk R/R MCL.

Methods: This is a prospective, single-center, single-arm phase II study in high-risk R/R MCL (NCT06656221). Patients received obinutuzumab pretreatment on C1D1, glofitamab step-up dosing per recommended schedule (2.5 mg C1D8, 10 mg C1D15, then 30 mg every 3 weeks on C2–C12 D1), bortezomib 1.6 mg/m² (D1/D8/D15, C1–C12), and orelabrutinib 150 mg daily. The primary endpoint was investigator-assessed CR rate by FDG-PET adopting the 2014 Lugano criteria. Responses were assessed at scheduled protocol time points; best overall response was analyzed in the efficacy-evaluable population (≥1 post-baseline assessment). Adverse events were graded per CTCAE v5.0 and cytokine release syndrome (CRS) per ASTCT criteria.

Results: As of the July 2026 data cutoff (median follow-up 12.3 months), 20 high-risk R/R MCL patients were enrolled. Median age was 67 years (range 52–84), 8 (40%) ≥70 years, and 15 (75%) were male. The median prior treatment lines were 1 (range 1–4); 6 patients (30%) received ≥2 prior lines (1 patient with 4 prior lines including a BTKi), and 50% of patients were refractory to last-line therapy. Fifteen patients completed ≥6 cycles and were efficacy-evaluable. The best overall response (BOR) was CR in all 15/15 (100%), yielding a CR rate and objective response rate (ORR) of 100%. Responses were consistent across patients with 1 prior line and ≥2 prior lines. Despite limited follow-up, 12/15 patients remain in ongoing remission, while 3 patients subsequently developed progressive disease. Notably, all three progressing patients achieved remission after 2 cycles and demonstrated CD20 loss at disease progression, consistent with CD20 antigen escape. The triplet was generally tolerable. CRS commonly occurred (14/15, 93%), all grade 1–2 (4/15 grade 2) without grade ≥3 events. The most common grade 3–4 adverse events were neutropenia (9, 60%), thrombocytopenia (7, 47%), and infections (2, 13%). No treatment-related deaths were reported.

Conclusions: This glofitamab-based triplet achieves high CR rates with manageable toxicity in high-risk R/R MCL, regardless of prior treatment lines. Early remissions appear durable, and CD20 antigen escape is the predominant mechanism of treatment failure. Enrollment and extended follow-up are ongoing to evaluate response duration and progression-free survival, supporting further investigation of this combination.
Li Wang III, MD: No relevant conflicts of interest to declare.